|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Table 1. Descriptive statistics | Cases | | Controls | |
|  | **nobs** | **Mean/median** | **nobs** | **Mean/median** |
| Age at blood sampling (years) | 224 | 59.8 (IQR: 50.1 - 60.1; range: 29.8 - 69.9) | 224 | 59.9 (IQR: 50.2 - 60.2; range: 30.2 - 72.9) |
| Age at event (years) | 224 | 64.6 (IQR: 58.7 - 68.7; range: 40.6 - 74.9) |  |  |
| Sex | 224 |  | 224 |  |
| female |  | 46 (20.5 %) |  | 46 (20.5 %) |
| male |  | 178 (79.5 %) |  | 178 (79.5 %) |
| Serum total cholesterol (mmol/L) | 216 | 6.43 (SD: ± 1.32) | 214 | 6.09 (SD: ± 1.14) |
| Apolipoprotein B-100 (g/L) | 170 | 1.32 (SD: ± 0.292) | 173 | 1.17 (SD: ± 0.254) |
| Apolipoprotein A-1 (g/L) | 169 | 1.36 (SD: ± 0.211) | 173 | 1.42 (SD: ± 0.255) |
| Body mass index (kg/m2) | 223 | 27.1 (IQR: 25.2 - 29.7; range: 19.9 - 44.8) | 219 | 25.6 (IQR: 23.2 - 27.8; range: 17.9 - 40.7) |
| Systolic blood pressure (mmHg) | 220 | 142 (SD: ± 20) | 220 | 133 (SD: ± 18) |
| Diastolic blood pressure(mmHg) | 220 | 86.7 (SD: ± 10.9) | 220 | 82.3 (SD: ± 10.2) |
| Current smoker | 218 |  | 213 |  |
| no |  | 136 (62.4 %) |  | 163 (76.5 %) |
| yes |  | 82 (37.6 %) |  | 50 (23.5 %) |
| Glucose (mmol/L) | 201 | 5.5 (IQR: 5.05 - 6.2; range: 3.9 - 26.9) | 204 | 5.4 (IQR: 5.09 - 5.9; range: 2.9 - 12.5) |
| Post-OGTT glucose (mmol/L) | 170 | 6.42 (IQR: 5.31 - 7.9; range: 1.9 - 21.3) | 194 | 6.4 (IQR: 5.5 - 7.34; range: 2.9 - 18.5) |
| Self-reported diabetes | 223 |  | 218 |  |
| no |  | 200 (89.7 %) |  | 213 (97.7 %) |
| yes |  | 23 (10.3 %) |  | 5 (2.3 %) |
| Fasting status | 224 |  | 224 |  |
| 0-4h |  | 14 (6.2 %) |  | 10 (4.5 %) |
| 4-6h |  | 43 (19.2 %) |  | 39 (17.4 %) |
| 6-8h |  | 6 (2.7 %) |  | 2 (0.9 %) |
| >8h |  | 161 (71.9 %) |  | 173 (77.2 %) |
| Secondary education | 209 |  | 212 |  |
| no |  | 117 (56 %) |  | 87 (41 %) |
| yes |  | 92 (44 %) |  | 125 (59 %) |
| ECG | 224 |  |  |  |
| LBBB |  | 1 (0.4 %) |  |  |
| NSTEMI |  | 6 (2.7 %) |  |  |
| Unknown |  | 3 (1.3 %) |  |  |
| PM |  | 0 (0 %) |  |  |
| SCD |  | 187 (83.5 %) |  |  |
| STEMI |  | 27 (12.1 %) |  |  |
| Estimated time to death  from symptom onset | 224 |  |  |  |
| <1h |  | 108 (48.2 %) |  |  |
| 1-24h |  | 68 (30.4 %) |  |  |
| Unknown |  | 48 (21.4 %) |  |  |
| Self-reported blood pressure lowering drug intake during the past two weeks | 216 |  | 204 |  |
| no |  | 151 (69.9 %) |  | 179 (87.7 %) |
| yes |  | 65 (30.1 %) |  | 25 (12.3 %) |
| Self-reported ASA or nitroglycerin drug intake during the past two weeks | 216 |  | 204 |  |
| no |  | 192 (88.9 %) |  | 194 (95.1 %) |
| yes |  | 24 (11.1 %) |  | 10 (4.9 %) |
| Self-reported benzodiazepine or antihistamine drug during the past two weeks | 193 |  | 181 |  |
| no |  | 185 (95.9 %) |  | 176 (97.2 %) |
| yes |  | 8 (4.1 %) |  | 5 (2.8 %) |
| Self-reported proton pump inhibitor drug intake during the past two weeks | 155 |  | 150 |  |
| no |  | 146 (94.2 %) |  | 139 (92.7 %) |
| yes |  | 9 (5.8 %) |  | 11 (7.3 %) |
| Self-reported lipid lowering drug intake during the past two weeks | 177 |  | 173 |  |
| no |  | 158 (89.3 %) |  | 172 (99.4 %) |
| yes |  | 19 (10.7 %) |  | 1 (0.6 %) |
| Lifestyle and diet DM2 treatment | 204 |  | 203 |  |
| no |  | 200 (98 %) |  | 202 (99.5 %) |
| yes |  | 4 (2 %) |  | 1 (0.5 %) |
| Lifestyle, diet and drug DM2 treatment | 204 |  | 203 |  |
| no |  | 199 (97.5 %) |  | 201 (99 %) |
| yes |  | 5 (2.5 %) |  | 2 (1 %) |
| Lifestyle, diet, drug, and insulin DM2 treatment | 204 |  | 203 |  |
| no |  | 196 (96.1 %) |  | 203 (100 %) |
| yes |  | 8 (3.9 %) |  | 0 (0 %) |